TY - JOUR
T1 - Relationship between serum levels of insulin-like growth factors and subsequent risk of cancer mortality
T2 - Findings from a nested case-control study within the Japan Collaborative Cohort Study
AU - Pham, Truong Minh
AU - Fujino, Yoshihisa
AU - Nakachi, Kei
AU - Suzuki, Koji
AU - Ito, Yoshinori
AU - Watanabe, Yoshiyuki
AU - Inaba, Yutaka
AU - Tajima, Kazuo
AU - Tamakoshi, Akiko
AU - Yoshimura, Takesumi
N1 - Funding Information:
The authors express their sincere appreciation to Dr. Kunio Aoki, Professor Emeritus, Nagoya University School of Medicine and the former chairman of the JACC Study; Dr. Haruo Sugano, former Director of the Cancer Institute, Tokyo, who greatly contributed to the initiation of the JACC Study; and Dr. Yoshiyuki Ohno, Professor Emeritus, Nagoya University School of Medicine, who was the past chairman of the study. The authors also wish to thank Dr. Tomoyuki Kitagawa, Cancer Institute of the Japanese Foundation for Cancer Research and former chairman of the Grant-in-Aid for Scientific Research on Priority Area Cancer, for his full support of this study. Dr. Truong-Minh Pham was awarded a Postdoctoral Scientist Fellowship by a Grant-in-Aid from the Japan Society for the Promotion of Sciences.
Funding Information:
Grants: The JACC Study has been supported by Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (Nos. 61010076, 62010074, 63010074, 1010068, 2151065, 3151064, 4151063, 5151069, 6279102, and 11181101, 17015022, 18014011, 20014026).
PY - 2010/6
Y1 - 2010/6
N2 - Background: We investigated the association between serum levels of IGF-I, IGF-II, and IGFBP-3 and the subsequent risk of cancer mortality. Methods: Our case-control study examined samples from 914 cancer deaths and their 2739 matched controls within the Japan Collaborative Cohort Study. Blood samples were obtained at the baseline and stored at -80 °C until analysis for IGF-I, IGF-II, and IGFBP-3 levels. The conditional logistic model was used to estimate odds ratios (ORs) for cancer mortality associated with these serum levels. Results: The adjusted ORs for IGF-I quartiles ranged from 0.81 to 0.96 but were not significant. The adjusted ORs and 95% confidence interval (CI) for the second, third, and fourth IGF-II quartiles were 0.64 (95% CI: 0.52-0.79), 0.71 (95% CI: 0.58-0.88), and 0.73 (95% CI: 0.59-0.91), respectively, while those for the respective IGFBP-3 quartiles were 0.77 (95% CI: 0.63-0.96), 0.75 (95% CI: 0.60-0.94), and 0.71 (95% CI: 0.56-0.90). In the model of IGF-I, and IGF-II additionally adjusted for IGFBP-3, the associations of high IGFs levels were similar as observed in the above models, while the association of IGFBP-3 shifted into non-significance after adjusting for IGF-II. Conclusion: An increased level of IGF-II was significantly associated with decreased risk of cancer mortality, whereas the association between IGF-I and all cancer mortality was not significant. The inverse association of IGFBP-3 level with all cancer mortality was affected when adjusting for IGF-II levels, shifting from significant to non-significant. Confirmation of these results from further cohort studies may aid in identifying the potential association between these molecules and the risk of cancer among the general Japanese population.
AB - Background: We investigated the association between serum levels of IGF-I, IGF-II, and IGFBP-3 and the subsequent risk of cancer mortality. Methods: Our case-control study examined samples from 914 cancer deaths and their 2739 matched controls within the Japan Collaborative Cohort Study. Blood samples were obtained at the baseline and stored at -80 °C until analysis for IGF-I, IGF-II, and IGFBP-3 levels. The conditional logistic model was used to estimate odds ratios (ORs) for cancer mortality associated with these serum levels. Results: The adjusted ORs for IGF-I quartiles ranged from 0.81 to 0.96 but were not significant. The adjusted ORs and 95% confidence interval (CI) for the second, third, and fourth IGF-II quartiles were 0.64 (95% CI: 0.52-0.79), 0.71 (95% CI: 0.58-0.88), and 0.73 (95% CI: 0.59-0.91), respectively, while those for the respective IGFBP-3 quartiles were 0.77 (95% CI: 0.63-0.96), 0.75 (95% CI: 0.60-0.94), and 0.71 (95% CI: 0.56-0.90). In the model of IGF-I, and IGF-II additionally adjusted for IGFBP-3, the associations of high IGFs levels were similar as observed in the above models, while the association of IGFBP-3 shifted into non-significance after adjusting for IGF-II. Conclusion: An increased level of IGF-II was significantly associated with decreased risk of cancer mortality, whereas the association between IGF-I and all cancer mortality was not significant. The inverse association of IGFBP-3 level with all cancer mortality was affected when adjusting for IGF-II levels, shifting from significant to non-significant. Confirmation of these results from further cohort studies may aid in identifying the potential association between these molecules and the risk of cancer among the general Japanese population.
UR - http://www.scopus.com/inward/record.url?scp=77952185365&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952185365&partnerID=8YFLogxK
U2 - 10.1016/j.canep.2010.03.017
DO - 10.1016/j.canep.2010.03.017
M3 - Article
C2 - 20427254
AN - SCOPUS:77952185365
SN - 1877-7821
VL - 34
SP - 279
EP - 284
JO - Cancer Epidemiology
JF - Cancer Epidemiology
IS - 3
ER -